Shortcut menu

Contents Area

Scientific Program

ASGO 2019
"Optimal Gynecologic Cancer Care in Asia"

*Program is subject to change.

Daily Program
Time Program Speaker
[Symposium 3] Revised FIGO Stage of Cervix Cancer & Related Issues (90 min) Chair: Neerja Bhatla (India)
Co-chair: Jatupol Srisomboon (Thailand)
08:30-08:45 Validating new (2018) FIGO staging of cervix cancer Kailash Narayan (Australia)
08:45-09:00 Pathologic perspectives in revised FIGO Hyojin Kim (Korea)
09:00-09:15 Status of less-radical surgery in Japan Takahide Arimoto (Japan)
09:15-09:30 Predictive models for metastasis and recurrence after radical hysterectomy in patients with early-stage cervical cancer Kittipat Charoenkwan (Thailand)
09:30-09:45 Surgical staging in advanced stage Chel Hun Choi (Korea)
09:45-10:00 Discussion
[Symposium 4] Endometrial Cancer Update (90 min) Chair: Duk-Soo Bae (Korea)
Co-chair: Qi Zhou (China)
08:30-08:50 How to avoid futile LND in early stage endometrial cancer Sokbom Kang (Korea)
08:50-09:10 LND issues in endometrial cancer Hidemichi Watari (Japan)
09:10-09:30 Molecular classification of endometrial cancer Kidong Kim (Korea)
09:30-09:50 Preservation of ovary in the management of endometrial carcinoma Kun Song (China)
09:50-10:00 Discussion
[Education Session 3] ERAS (35 min) Chair: Dae-Sik Seo (Korea)
08:30-08:45 Pre and postoperative management in gynecologic cancer surgery with planned bowel resection Jung Myun Kwak (Korea)
08:45-09:00 Pain management and anesthetic issue Jin-Tae Kim (Korea)
09:00-09:05 Discussion
[Special Session 1] Molecular Dissection of Ovarian Clear Cell Carcinoma (50 min) Chair: Aikou Okamoto (Japan)
Co-chair: Jeong-Won Lee (Korea)
09:10-09:25 Ovarian clear cell carcinoma: molecular characterization of sensitivity to platinum-based chemotherapy Masataka Takenaka (Japan)
09:25-09:40 Molecular profiling of ovarian clear cell carcinomas: implications for therapy Ruby Huang (Taiwan)
09:40-09:55 Genomics to immunotherapy of ovarian clear cell carcinoma Katsutoshi Oda (Japan)
09:55-10:00 Discussion
[Plenary Session 2] Surgical Issues in Gynecologic Oncology Field (110 min) Chair: Daisuke Aoki (Japan)
Co-chair: Young-Tae Kim (Korea)
2nd debulking in epithelial ovarian cancer 10:20-10:35 Surgery for recurrent ovarian cancer. Evidence from DESKTOP series and others Andreas du Bois (Germany)
10:35-10:50 GOG 213 surgical part Robert Coleman (USA)
10:50-11:05 Selection criteria and principles for 2nd debulking surgery: expert point of view Dennis Chi (USA)
11:05-11:15 Discussion
Surgical approach in early stage cervical cancer after LACC 11:15-11:30 Real problems of laparoscopic radical hysterectomy Joo-Hyun Nam (Korea)
11:30-11:45 Asian viewpoint Mikio Mikami (Japan)
11:45-12:00 American and the other world viewpoint Mario Leitao (USA)
12:00-12:10 Discussion
[Special Symposium 2] (20 min) Chair: Seob Jeon (Korea)
12:20-12:40 Role of bevacizumab in ovarian cancer & evolution as backbone of novel combination Mansoor R Mirza (Denmark)
[Plenary Session 3] PAPRi, Immuno-Oncology and Beyond (90 min) Chair: Seung Cheol Kim (Korea)
Co-chair: Xing Xie (China)
13:10-13:30 PARP inhibition in ovarian cancer: is it time for a paradigm shift? Richard Penson (USA)
13:30-13:50 Prevalence of BRCA mutation and real world experience of PAPRi Byoung-Gie Kim (Korea)
13:50-14:10 Biomarkers for immunotherapy usage in gynecologic cancer Wei Zhou (USA)
14:10-14:30 Novel and emerging agents under development for gynecologic cancers Wen Yee Chay (Singapore)
14:30-14:40 Discussion
[Symposium 5] Hereditary Breast and Ovarian Cancer in Asia (90 min) Chair: Takayuki Enomoto (Japan)
Co-chair: Wen-Fang Cheng (Taiwan)
15:00-15:20 Establishing BRCA consortium in Asia Sung-Won Kim (Korea)
15:20-15:40 Strategies of genetic test and counseling in Asia Masayuki Sekine (Japan)
15:40-16:00 Clinical impact of hereditary predisposition in gynecologic cancer Myong-Cheol Lim (Korea)
16:00-16:20 A need of Asian guidelines for the management of BRCA carrier Arb-aroon Lertkhachonsuk (Thailand)
16:20-16:30 Discussion
[Symposium 6] MIS in gynecologic cancer management (90 min) Chair: Nobuo Yaegashi (Japan)
Co-chair: Soo Young Hur (Korea)
15:00-15:15 Sentinel lymph node biopsy  in cervical and vulvar cancer Mario Leitao (USA)
15:15-15:30 Robotic approach for high-risk endometrial cancer Jiheum Paek (Korea)
15:30-15:45 Sentinel lymph node staging experience in Thailand Nuttavut Kantathavorn (Thailland)
15:45-16:00 Two-step sentinel lymph node mapping strategy in endometrial cancer Sang-Wun Kim (Korea)
16:00-16:15 Current role of minimally invasive surgery for ovarian cancer Jeong-Yeol Park (Korea)
16:15-16:30 Discussion
Ovarian Cancer Roundtable Session of Chinese Gynecologic Oncologists (15:00-17:00)
15:00-15:10 Opening
Part 1 Jihong Liu (China)
15:10-15:40 Cornerstone recent advances in surgery of ovarian cancer Jianqing Zhu (China)
15:40-16:00 Discussion Discussion Leader:
Yang Xiang (China)
Part 2 Qi Zhou (China)
16:00-16:30 Milestone · advances in targeted therapy in ovarian cancer Rutie Yin (China)
16:30-16:50 Discussion Discussion Leader:
Yang Xiang (China)
16:50-17:00 Closing Xing Xie (China),
Rongyu Zang (China)
[Oral 3] TR in Ovarian Cancer (90 min) Chair: Sarikapan Wilailak (Thailand)
Co-chair: Ting-Chang Chang (Taiwan)
15:00-15:10 Antitumor effect of FGFR inhibitor AZD4547 in ovarian cancer cells Tae-Kyu Jang (Korea)
15:10-15:20 Survival prognosis of uterine-preserving surgery on stage I primary mucinous epithelial ovarian carcinoma Kaname Uno (Japan)
15:20-15:30 YAP silencing using dobutamine-PLGA nanoparticle as a new therapeutic strategy for ovarian cancer Ju-Won Roh (Korea)
15:30-15:40 Tyrosine kinase receptor TIE-1 mediates cell growth by regulating PI3K/Akt signaling pathway in PI3K-high-expressing ovarian cancer Xuewei Zhang (Japan)
15:40-15:50 First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors Wen Yee Chay (Singapore)
15:50-16:00 The roles of androgen receptor in chemosensitivity in serous ovarian cancer Hung-Chun Fu (Taiwan)
16:00-16:10 Cancer stem cell (CD133, CD44 and ALDH1A1) markers as prognostic factors on epithelial ovarian cancer Nugraha Pelupessy (Indonesia)
16:10-16:20 Low expression of gamma-glutamyl transpeptidase 1 is an independent poor prognostic factor associated with up-regulation of immune suppressive genes and EMT-related genes in ovarian clear cell carcinoma Hiroshi Asano (Japan)
16:20-16:30 The role Of Akt2, and CA-125 serum levels as predictors for cytoreduction in epithelial ovarian cancer surgery Yudi Mulyana Hidayat (Indonesia)
[Education Session 4] Surgical and Molecular Tumor Board (90 min) Chair: Sang Young Ryu (Korea)
Co-chair: Xiaoping Li (China)
Case Presentation 1 16:50-17:00 Case presentation: cervix cancer U Chul Ju (Korea)
17:00-17:15 Comments on of the cervical cancer management Hung-Cheng Lai (Taiwan)
17:15-17:20 Discussion
Case Presentation 2 17:20-17:30 Case presentation: endometrial cancer Yiqin Wang (China)
17:30-17:45 Comments on various aspects of the case management Janice Kwon (Canada)
17:45-17:50 Discussion
Case Presentation 3 17:50-18:00 Case presentation: epithelial ovarian cancer Won-Kyo Shin (Korea)
18:00-18:15 Comments on various aspects of the case management Masaki Mandai (Japan)
18:15-18:20 Discussion
[Oral 4] Issues in Surgical Treatment (80 min) Chair: Kung-Liahng Wang (Taiwan)
Co-Chair: Yoon-Soon Lee (Korea)
16:50-17:00 Risk factors for lymph node metastasis according to LVSI in apparent uterine-confined endometrial cancer Joo-Hyuk Son (Korea)
17:00-17:10 Development of novel diagnosis method of uterine cancer using lymph node metastasis predictive biomarker for more personalized lymphadenectomy Emiko Yoshida (Japan)
17:10-17:20 Comparison of ROMA algorithm and CA 125 as tools for discriminate benign ovarian tumor and early stage ovarian cancer according to imaging tumor subtypes that connected to postoperative histopathologic findings Youngjae Lee (Korea)
17:20-17:30 Inadvertent ovarian malignancy following operative laparoscopy of adnexal masses: university malaya medical centre experience Muhammad Asyaraf Azizan (Malaysia)
17:30-17:40 Analysis of factors influencing the recurrence and fertility outcomes of ovarian borderline tumors Zhengmao Zhang (China)
17:40-17:50 The effect of pelvic and para-aortic lymphadenectomy for clinically-apparent stage I endometrioid epithelial ovarian carcinoma Masato Yoshihara (Japan)
17:50-18:00 Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary Shohei Iyoshi (Japan)
18:00-18:10 Knowledge, attitude and practices of gynecologists in a tertiary hospital on preoperative bowel preparation Romelyn Imperio-Onglao (Philippines)
[Special Session 2] ASGO-AOGIN Joint Session: How to Collaborate to Eliminate Cervical Cancer in Asia-Pacific Region (90 min) Chair: EH Tay (Singapore)
Co-chair: Young-Tak Kim (Korea)
16:50-17:10 Elimination of cervical cancer: global overview and prospects for Asia Neerja Bhatla (India)
17:10-17:30 VIA with picture as one option strategy in increasing the cervical cancer screening coverage in low resource setting area Dwiana Ocviyanti (Indonesia)
17:30-17:50 HPV test as a primary cervical cancer screening Warner Huh (USA)
17:50-18:10 Cost-effectiveness of primary HPV test and triage test in cervical cancer screening Wichai Termrungruanglert (Thailand)
18:10-18:20 Discussion

Site Information & Copyright Area